CORT
Corcept Therapeutics Incorporated
CORT
Corcept Therapeutics Incorporated
NEW YORK, Sept. 4, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P 100, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of tradi
Corcept Therapeutics is rated Strong Buy with $163 one-year and $222 two-year price targets, driven by explosive revenue and margin expansion. Lifyorli's rapid launch for platinum-resistant ovarian ca
Corcept Therapeutics Incorporated (CORT) Q2 2026 Earnings Call Transcript
Corcept Therapeutics maintains a Buy rating, supported by robust revenue growth, pipeline progress, and strong management execution. Relacorilant's FDA approval in ovarian cancer and likely approval i